{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:17:45Z","timestamp":1783415865686,"version":"3.54.6"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Recent evidence cautions against the use of non-selective beta-blockers (NSBB) in patients with refractory ascites or spontaneous bacterial peritonitis while other data suggests a survival benefit in patients with advanced liver disease. The aim of this study was to describe the use and impact of NSBB in patients with cirrhosis referred for liver transplantation.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A single-center cohort of patients with cirrhosis, who were referred and evaluated for liver transplantation between January and June 2012 were studied for baseline characteristics and clinical outcomes. Patients were grouped according to the use of NSBB at initial evaluation, with the endpoint of 90-day mortality.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Sixty-five (38%) of 170 consecutive patients evaluated for liver transplantation were taking NSBB. Patients taking NSBB had higher MELD and Child Pugh score. NSBB use was associated with lower 90-day mortality (6% vs. 15%) with a risk adjusted hazard ratio of 0.27 (95%CI .09\u20130.88, <jats:italic>p<\/jats:italic>\u2009=\u2009.03). Patients taking NSBB developed acute kidney injury (AKI) within 90\u2009days more frequently than patients not taking NSBB (22% vs 11%), <jats:italic>p<\/jats:italic>\u2009=\u20090.048). However, this was related to increased stage 1 AKI episodes, all of which resolved. Twelve (27%) of 45 patients with &gt;\u200990\u2009day follow up discontinued NSBB, most commonly for hypotension and AKI, had increased subsequent MELD and mortality.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>NSBB use in patients with cirrhosis undergoing liver transplant evaluation is associated with better short-term survival. Nevertheless, ongoing tolerance of NSBB in this population is dynamic and may select a subset of patients with better hemodynamic reserve.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12876-019-1155-1","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T18:04:00Z","timestamp":1578333840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation"],"prefix":"10.1186","volume":"20","author":[{"given":"Taiwo","family":"Ngwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Orman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Vilar","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Vuppalanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrashekhar","family":"Kubal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-3246","authenticated-orcid":false,"given":"Marwan","family":"Ghabril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"issue":"3","key":"1155_CR1","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/hep.20584","volume":"41","author":"J de la Pena","year":"2005","unstructured":"de la Pena J, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology. 2005;41(3):572\u20138.","journal-title":"Hepatology"},{"issue":"3","key":"1155_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jhep.2013.09.016","volume":"60","author":"PS Ge","year":"2014","unstructured":"Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol. 2014;60(3):643\u201353.","journal-title":"J Hepatol"},{"issue":"3","key":"1155_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/hep.23045","volume":"50","author":"D Tripathi","year":"2009","unstructured":"Tripathi D, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology. 2009;50(3):825\u201333.","journal-title":"Hepatology"},{"issue":"9","key":"1155_CR4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJMra0901512","volume":"362","author":"G Garcia-Tsao","year":"2010","unstructured":"Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362(9):823\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"1155_CR5","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1053\/jhep.2003.50133","volume":"37","author":"JG Abraldes","year":"2003","unstructured":"Abraldes JG, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37(4):902\u20138.","journal-title":"Hepatology"},{"issue":"3","key":"1155_CR6","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/ajg.2011.456","volume":"107","author":"V Hernandez-Gea","year":"2012","unstructured":"Hernandez-Gea V, et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with beta-blockers. Am J Gastroenterol. 2012;107(3):418\u201327.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1155_CR7","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","volume":"58","author":"T Reiberger","year":"2013","unstructured":"Reiberger T, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58(5):911\u201321.","journal-title":"J Hepatol"},{"issue":"8","key":"1155_CR8","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/j.1478-3231.2009.02038.x","volume":"29","author":"M Senzolo","year":"2009","unstructured":"Senzolo M, et al. Beta-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int. 2009;29(8):1189\u201393.","journal-title":"Liver Int"},{"issue":"4","key":"1155_CR9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1136\/gut.2004.048181","volume":"54","author":"U Thalheimer","year":"2005","unstructured":"Thalheimer U, et al. Infection, coagulation, and variceal bleeding in cirrhosis. Gut. 2005;54(4):556\u201363.","journal-title":"Gut"},{"issue":"3","key":"1155_CR10","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.23775","volume":"52","author":"T Serste","year":"2010","unstructured":"Serste T, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010;52(3):1017\u201322.","journal-title":"Hepatology"},{"issue":"7","key":"1155_CR11","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1053\/j.gastro.2014.03.005","volume":"146","author":"M Mandorfer","year":"2014","unstructured":"Mandorfer M, et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146(7):1680\u201390 e1.","journal-title":"Gastroenterology"},{"issue":"1","key":"1155_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/gut.2009.180570","volume":"59","author":"A Krag","year":"2010","unstructured":"Krag A, et al. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59(1):105\u201310.","journal-title":"Gut"},{"issue":"7","key":"1155_CR13","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/gutjnl-2011-301348","volume":"61","author":"A Krag","year":"2012","unstructured":"Krag A, et al. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut. 2012;61(7):967\u20139.","journal-title":"Gut"},{"issue":"8","key":"1155_CR14","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.cgh.2016.01.012","volume":"14","author":"S Chirapongsathorn","year":"2016","unstructured":"Chirapongsathorn S, et al. Nonselective beta-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(8):1096\u2013104 e9.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"1155_CR15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1136\/gutjnl-2013-306502","volume":"64","author":"JA Leithead","year":"2015","unstructured":"Leithead JA, et al. Non-selective beta-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut. 2015;64(7):1111\u20139.","journal-title":"Gut"},{"issue":"6","key":"1155_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/lt.24744","volume":"23","author":"SG Kim","year":"2017","unstructured":"Kim SG, et al. Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates. Liver Transpl. 2017;23(6):733\u201340.","journal-title":"Liver Transpl"},{"issue":"4","key":"1155_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/gutjnl-2014-308874","volume":"64","author":"P Angeli","year":"2015","unstructured":"Angeli P, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64(4):531\u20137.","journal-title":"Gut"},{"issue":"2","key":"1155_CR18","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/0016-5085(88)90441-6","volume":"94","author":"J Llach","year":"1988","unstructured":"Llach J, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology. 1988;94(2):482\u20137.","journal-title":"Gastroenterology"},{"issue":"9","key":"1155_CR19","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/liv.13409","volume":"37","author":"Simona Onali","year":"2017","unstructured":"Onali S, et al. Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites. Liver Int. 2017;37(9):1334\u201344.","journal-title":"Liver International"},{"issue":"8","key":"1155_CR20","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/lt.24794","volume":"23","author":"C Moctezuma-Velazquez","year":"2017","unstructured":"Moctezuma-Velazquez C, Kalainy S, Abraldes JG. Beta-blockers in patients with advanced liver disease: has the dust settled? Liver Transpl. 2017;23(8):1058\u201369.","journal-title":"Liver Transpl"},{"issue":"7","key":"1155_CR21","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/apt.14485","volume":"47","author":"N Pfisterer","year":"2018","unstructured":"Pfisterer N, et al. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. Aliment Pharmacol Ther. 2018;47(7):966\u201379.","journal-title":"Aliment Pharmacol Ther"},{"key":"1155_CR22","doi-asserted-by":"crossref","unstructured":"The Italian Multicenter Project for Propranolol in Prevention of Bleeding\" as institutional author name and  \"Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of a multicenter randomized trial. J Hepatol. 1989;9(1):75\u201383.","DOI":"10.1016\/0168-8278(89)90078-0"},{"issue":"6","key":"1155_CR23","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1002\/hep.28352","volume":"63","author":"L Bossen","year":"2016","unstructured":"Bossen L, et al. Nonselective beta-blockers do not affect mortality in cirrhosis patients with ascites: post hoc analysis of three randomized controlled trials with 1198 patients. Hepatology. 2016;63(6):1968\u201376.","journal-title":"Hepatology"},{"issue":"16","key":"1155_CR24","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1056\/NEJMra035021","volume":"350","author":"P Gines","year":"2004","unstructured":"Gines P, et al. Management of cirrhosis and ascites. N Engl J Med. 2004;350(16):1646\u201354.","journal-title":"N Engl J Med"},{"issue":"4","key":"1155_CR25","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2011.01.034","volume":"55","author":"T Serste","year":"2011","unstructured":"Serste T, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011;55(4):794\u20139.","journal-title":"J Hepatol"},{"issue":"5","key":"1155_CR26","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1053\/jhep.2003.50447","volume":"38","author":"L Ruiz-del-Arbol","year":"2003","unstructured":"Ruiz-del-Arbol L, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003;38(5):1210\u20138.","journal-title":"Hepatology"},{"issue":"11","key":"1155_CR27","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1136\/gutjnl-2015-309262","volume":"64","author":"D Tripathi","year":"2015","unstructured":"Tripathi D, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015;64(11):1680\u2013704.","journal-title":"Gut"},{"issue":"3","key":"1155_CR28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R de Franchis","year":"2015","unstructured":"de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743\u201352.","journal-title":"J Hepatol"},{"issue":"1","key":"1155_CR29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hep.28906","volume":"65","author":"G Garcia-Tsao","year":"2017","unstructured":"Garcia-Tsao G, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American association for the study of liver diseases. Hepatology. 2017;65(1):310\u201335.","journal-title":"Hepatology"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1155-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-019-1155-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1155-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:09:12Z","timestamp":1609805352000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-019-1155-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1155"],"URL":"https:\/\/doi.org\/10.1186\/s12876-019-1155-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,6]]},"assertion":[{"value":"1 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study is approved by the Institutional Review Board at Indiana University School of Medicine which abides by the guidance of the Declaration of Helsinki. This was a minimal risk study and consent requirements waived as a result. IRB number 1505555256.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}